“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors

Several evidences have shown that BRCA mutations increased tumor-cells sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated development of several compounds targeting the PARP enzymes system as anticancer agents for clinical setting. Most of such compounds have been invest...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Incorvaia, Lorena, Passiglia, Francesc, Rizzo, Sergio, Galvano, Antonio, Listȶ, Angela, Barraco, Nadia, Maragliano, Rossella, Calò, Valentina, Natoli, Clara, Ciaccio, Marcello, Bazan, Viviana, Russo, Antonio
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410353/
https://ncbi.nlm.nih.gov/pubmed/28055979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14409
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars